New York, February 3, 2026, 14:46 (EST) — Regular session
- BSX slipped roughly 0.7% in afternoon trading, bouncing between $93.01 and $90.85 earlier.
- Officer and director Michael F. Mahoney submitted a Form 144 notice indicating a potential sale of as many as 160,901 shares
- Earnings call scheduled for Wednesday morning; the next big event is the late-March Watchman trial readout
Boston Scientific (BSX.N) slipped roughly 0.7% to $91.20 in afternoon trading Tuesday, after fluctuating between $93.01 and $90.85. About 10.4 million shares changed hands.
The medtech firm will go over its fourth-quarter results Wednesday during an 8 a.m. ET conference call, according to its investor website. Investors will be watching not just the earnings but also the guidance and trends in procedure demand. (Boston Scientific Investors)
Josh Jennings of TD Cowen reaffirmed a Buy rating and held firm on a $115 price target, highlighting the late March CHAMPION-AF data for the Watchman implant as a pivotal catalyst. He’s looking for the results to drop at the American College of Cardiology meeting on March 28. (TipRanks)
CHAMPION-AF is testing left atrial appendage closure — a procedure that seals off a small heart pouch where clots may form — against newer oral anticoagulants in patients with atrial fibrillation, the company said. The trial aims to evaluate the device as a first-line treatment, potentially expanding its use if it meets the study’s endpoints. (Bostonscientific)
The stock dropped 1.8% Monday, ending at $91.87 on roughly 15.4 million shares traded, according to market data. (Investing)
A separate filing with the U.S. Securities and Exchange Commission revealed that Michael F. Mahoney, an officer and director, submitted a Form 144 notice to sell up to 160,901 shares via Morgan Stanley Smith Barney. The shares carry a combined market value near $15.0 million. Note that Form 144 signals a planned sale under SEC Rule 144 but doesn’t guarantee any shares have actually been sold. (Securities and Exchange Commission)
Abbott Laboratories dipped roughly 0.6% in the wider device sector, while Medtronic climbed around 1.0%. Edwards Lifesciences edged down about 0.4%.
Boston Scientific’s immediate focus will be how management outlines 2026. Procedure demand, pricing, and margins often influence the stock just as much as quarterly results do.
Analysts are forecasting earnings near 78 cents per share for the quarter, according to Kiplinger’s weekly earnings calendar. (Kiplinger)
Expectations can swing quickly around earnings. A cautious forecast or trial results that don’t change clinical practice away from blood thinners would probably dampen sentiment.
Wednesday’s report and the 8 a.m. ET call come first. Then all eyes turn to the March 28 CHAMPION-AF update, the next key date traders are watching closely.
